Tiziana Life Sciences Ltd (NASDAQ:TLSA) has presented posters on intranasal foralumab at the Preserving the Brain scientific conference, a scientific forum and exhibit on neurodegenerative diseases as part of human brains held at the Fondazione Prada in Milan, Italy.
Further, the company said the first secondary progressive multiple sclerosis patient receiving intranasal foralumab was interviewed by Tiziana scientific advisory board chairman Howard Weiner.
Intranasal foralumab is one of Tiziana’s two lead alternative immunotherapy drug candidates which has demonstrated a favorable safety profile and clinical response in patients in studies to date, according to the company.
READ: Tiziana Life Sciences reports continued improvements in second patient with secondary progressive multiple sclerosis after intranasal foralumab treatment
Tiziana interim CEO Gabriele Cerrone said he was thrilled that foralumab was highlighted at the Fondazione Prada’s Preserving the Brain international forum.
“Having the first patient to ever receive intranasal foralumab for secondary progressive multiple sclerosis interviewed at an esteemed cultural institution such as Fondazione Prada only further validates our passion and focus to advance this novel therapy,” he said.
Weiner’s patient interview, which was presented at the conference on September 27, can be watched here and the exhibited posters will be made available by the company after the conference.
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie